Summary:
- A moving average of Short volume ratio is at a recent 2 week high. A high short volume ratio indicate selling presures.
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Stock news
Generally speaking, investors are inspired to be stock pickers by the potential to find the big winners. But when you...
CRISPR Therapeutics (NASDAQ: CRSP) disappointed the market today with its third-quarter results, due in no small part to a dramatic but expected flip into the red on the bottom line. For similar reasons, CRISPR posted a loss in this most recent quarter.
-Reported positive top-line results from the Company’s ongoing Phase 1 CARBON trial evaluating the safety and efficacy of CTX110™, targeting CD19+ B-cell malignancies-\- Received Rare Pediatric Disease designation from the U.S. Food and Drug Administration (FDA) for CTX001™ for sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT)--Received Orphan Drug Designation (ODD) for Phase 1 clinical trial of CTX120™, targeting B-cell maturation antigen (BCMA)--Began treating pati...
Early signs of success with a revolutionary new type of cancer treatment make this biotech worth a closer look.
One analyst goes contrarian, raising her price target on the stock following some very dispiriting news from the company.
CRISPR Therapeutics (CRSP) reports top-line data from a phase I study, currently evaluating its pipeline candidate CTX110 for CD19+ B-cell malignancies. Shares down.
The biotech sector was in focus as Biogen's (BIIB) Q3 results disappoint, Vertex (VRTX) stops study and Regeneron's (REGN) Ebola drug gets FDA approval.
The death of a clinical trial participant overshadowed clear signs of efficacy for the company's off-the-shelf cellular therapy for non-Hodgkin lymphoma.